Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.03 - $9.50
Previous CloseN/A
Volume537.69K
Average Volume (3M)3.97M
Market Cap
$1.67B
Enterprise Value$2.08B
Total Cash (Recent Filing)$104.71M
Total Debt (Recent Filing)$808.74M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 01, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding208,960,020
10 Day Avg. Volume3,481,880
30 Day Avg. Volume3,972,980
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.70
Price to Cash Flow (P/CF)-80.00
P/FCF Ratio9.30
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.75
Enterprise Value/Ebitda223.15
Forecast
1Y Price Target
$14.73Price Target Upside82.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Product Launch And Market PositionOrladeyo's introduction as the first oral prophylactic treatment for HAE has captured approximately 20% market share, showcasing its competitive edge.
R&D And Pipeline DevelopmentBCX17725, targeting Netherton Syndrome, presents an intriguing opportunity for future growth as an underappreciated asset in the rare disease space.
Sales Performance And GuidanceBioCryst Pharmaceuticals raised its FY25 Orladeyo sales guidance to $535-550M, driven by higher-than-expected Medicare patient coverage and new prescription demand.
Bears Say
Competitive LandscapeDespite Orladeyo's market position, the increasing competitive landscape poses challenges for sustained growth.
Operational ExpensesThe stock experienced a 10% drop, likely due to an overreaction to higher-than-expected 4Q operational expenses.
---
Ownership Overview
6.69% Insiders
17.68% Mutual Funds
34.17% Other Institutional Investors
25.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $4.03 and its highest was $9.50 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.67B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Feb 24, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.084.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 208,960,020 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went down -9.989%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
---
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.73 (82.98% Upside)
$14.73 (82.98% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 255.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.35%
12-Months-Change
Fundamentals
Return on Equity
18.68%
Trailing 12-Months
Asset Growth
-5.13%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
---
BCRX Company Deck
---
BCRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance for BioCryst, with significant growth in Orladeo revenue, positive financial results, and advancements in the clinical pipeline. However, there are challenges with the reauthorization process and foreign exchange impacts, but they are outweighed by the company's achievements and growth projections.Read More>---
BCRX Stock 12 Month Forecast
Average Price Target
$14.73
▲(82.98% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Bluebird Bio
―
Best Analysts Covering BCRX
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+4.87%
reiterated a buy rating 29 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.87% per trade.
---